The acquisition of Tolimidone, which is ready for Phase II trials, could be a major milestone for Biodexa, potentially leading to increased investor confidence and a positive impact on the stock price in the short term. The news directly relates to Biodexa's core business and growth strategy, making it highly relevant and important for investors. The confidence score reflects the typical market response to expansion of product pipelines through licensing, although the actual impact will depend on further regulatory approvals and trial outcomes.